| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |